§ Federal grant opportunity · HT942526ALSRPPCTA
DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award
Jamie Shortall Grant Officer is accepting applications for DoW Amyotrophic Lateral Sclerosis Research Program, Pilot Clinical Trial Award. The deadline is September 30, 2026 and the published award range is Award amount not published.
Key facts
- Funder
- Jamie Shortall Grant Officer
- Application deadline
- September 30, 2026
- Award range
- Award amount not published
- Eligibility
- Eligibility criteria are published in the funding opportunity announcement.
- Geography
- United States
- Focus areas
- Research
- Opportunity number
- HT942526ALSRPPCTA
Program overview
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Pilot Clinical Trial Award (PCTA) supports the rapid implementation of clinical trials with the potential to have a significant impact on the treatment or management of amyotrophic lateral sclerosis (ALS). Projects may range from phase 1 to small-scale phase 2 trials. Applications must address one of the following focus areas: · Biomarker-Driven Interventions: Disease-modifying interventions, with mechanism-specific biomarkers to predict which clinical trial participants are likely to respond, demonstrate target engagement, and effects on the intended biological pathway. · Clinical Care: Improving aspects of clinical care and symptom management for ALS. Distinctive Features: Funding from this award mechanism must support a clinical trial. The clinical trial should begin no later than 12 months after the award date or 18 months for U.S. Food and Drug Administration (FDA)-regulated studies. Projects proposing a therapeutic intervention (drug, biologic, and/or device) must incorporate biomarkers specific to the intervention into the trial design. All pre-applications and applications are required to incorporate community collaboration, as described in Section 3.2.2, to optimize research impact. Applications must include a detailed Regulatory Strategy plan that outlines the approach for obtaining regulatory approvals, if required, specifically for the funded portion of the study. In addition, applications must provide a separate Transition Plan that describes how the outcomes of the study will be advanced to the next phase of development, beyond the scope of the funded work.
How to apply
- Confirm your organization meets the eligibility criteria above.
- Read the full funding opportunity announcement from Jamie Shortall Grant Officer.
- Draft your narrative against the funder's stated priorities and review criteria.
- Submit before September 30, 2026, allowing time for registration and validation.
Related grant opportunities
- DoW Breast Cancer, Transformative Breast Cancer Consortium Award
- DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Idea Award
- DoW Amyotrophic Lateral Sclerosis Research Program, Clinical Outcomes and Biomarkers Award
- DoW Breast Cancer, Breakthrough Award Level 3
- DoW Rare Cancers Concept Award
Find every grant your organization qualifies for
Mavenly scores this opportunity against your mission, geography, and funding history — then drafts the proposal with you and tracks the deadline through submission and reporting.